KeyBank National Association’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-10,091
Closed -$385K 1088
2023
Q3
$385K Sell
10,091
-1,088
-10% -$45.8K ﹤0.01% 789
2023
Q2
$460K Buy
11,179
+100
+0.9% +$4.81K ﹤0.01% 738
2023
Q1
$636K Buy
11,079
+6,340
+134% +$357K ﹤0.01% 602
2022
Q4
$266K Buy
+4,739
New +$241K ﹤0.01% 908
2016
Q2
Sell
-22,186
Closed -$747K 1114
2016
Q1
$747K Sell
22,186
-4,304
-16% -$134K 0.01% 655
2015
Q4
$898K Sell
26,490
-16,496
-38% -$516K 0.01% 598
2015
Q3
$1.28M Sell
42,986
-19,871
-32% -$621K 0.01% 484
2015
Q2
$1.73M Sell
62,857
-33,776
-35% -$900K 0.01% 432
2015
Q1
$2.44M Sell
96,633
-6,102
-6% -$144K 0.02% 359
2014
Q4
$2.28M Sell
102,735
-244
-0.2% -$4.95K 0.02% 364
2014
Q3
$2.09M Sell
102,979
-734
-0.7% -$14.6K 0.01% 377
2014
Q2
$2M Buy
103,713
+6,116
+6% +$114K 0.01% 415
2014
Q1
$1.83M Buy
97,597
+5,526
+6% +$107K 0.01% 438
2013
Q4
$1.8M Buy
92,071
+26,442
+40% +$485K 0.01% 444
2013
Q3
$1.08M Buy
+65,629
New +$1.05M 0.01% 604

Other funds holding IART

KeyBank National Association's IART Position: Q4 2023 in Review

KeyBank National Association sold out of Integra LifeSciences (IART) in Q4 2023, closing a stake of 10,091 shares — an estimated $385K sold.

KeyBank National Association first reported a position in IART in Q3 2013 and held it in 15 quarters. The position peaked at $2.44M in Q1 2015. 284 funds tracked by Wall St. Rank hold IART as of Q4 2023.

  • KeyBank National Association reported no remaining Integra LifeSciences position as of Q4 2023 after selling out during the quarter.
  • KeyBank National Association sold 10,091 Integra LifeSciences shares in Q4 2023, an estimated $385K.
  • KeyBank National Association first reported a position in Integra LifeSciences in Q3 2013 and held it in 15 quarters.
  • KeyBank National Association's Integra LifeSciences position peaked at $2.44M in Q1 2015.
  • 284 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2023.

Based on KeyBank National Association's 13F filing for Q4 2023, filed 13 Feb 2024.